Cancer cells alter their metabolism for the production of precursors of macromolecules. However, the control mechanisms underlying this reprogramming are poorly understood. Here we show that metabolic reprogramming of colorectal cancer is caused chiefly by aberrant MYC expression. Multiomics-based analyses of paired normal and tumor tissues from 275 patients with colorectal cancer revealed that metabolic alterations occur at the adenoma stage of carcinogenesis, in a manner not associated with specific gene mutations involved in colorectal carcinogenesis. MYC expression induced at least 215 metabolic reactions by changing the expression levels of 121 metabolic genes and 39 transporter genes. Further, MYC negatively regulated the expression of genes involved in mitochondrial biogenesis and maintenance but positively regulated genes involved in DNA and histone methylation. Knockdown of MYC in colorectal cancer cells reset the altered metabolism and suppressed cell growth. Moreover, inhibition of MYC target pyrimidine synthesis genes such as CAD, UMPS, and CTPS blocked cell growth, and thus are potential targets for colorectal cancer therapy.
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metabolomics | omics | metabolism | colorectal cancer | MYC O ne of the prominent characteristics of rapidly growing tumor cells is their capacity to sustain high rates of glycolysis for ATP generation irrespective of oxygen availability, termed the Warburg effect (1) . Recent studies have shown that cancer cells shift metabolic pathways to facilitate the uptake and incorporation of abundant nutrients, such as glucose and glutamine (2, 3) , into cell building blocks, such as nucleotides, amino acids, and lipids, that are essential for highly proliferating cells (4) . This seems to be a universal characteristic of highly malignant tumors (5) , independent of their carcinogenetic origin (6) . Understanding how cancer cells reprogram metabolism can stimulate the development of new approaches in cancer therapy.
Although there is now substantial information about how these pathways are regulated, most existing studies on cancer metabolism have used in vitro cell lines. In addition to genetic and epigenetic alterations, altered tumor microenvironment (e.g., blood flow, oxygen and nutrient supply, pH distribution, redox state, and inflammation) plays a profound role in modulating tumor cell metabolism (7) (8) (9) . Therefore, a systematic characterization of in vivo metabolic pathways was deemed necessary to understand how metabolic phenotypes are regulated in intact human tumors.
Here we applied multiomics-based approaches [i.e., metabolomics, target sequencing of cancer-related genes, transcriptomics, and methylated DNA immunoprecipitation sequencing (MeDIPseq)] to paired normal and tumor tissues obtained from 275 patients with colorectal cancer (CRC) and uncovered the details of which factors contributed, and when they contributed, to metabolic reprogramming in colorectal cancer. The results were confirmed by analysis of colorectal tissue from Apc mutant mice and cancer cell lines.
Results
Multiomics Analyses of Tumor and Normal Tissue from CRC. To explore the mechanisms that underlie the reprogramming of cancer cell metabolism, we performed capillary electrophoresis time-of-flight mass spectrometry-based metabolome profiling (10, 11) of paired tumor and normal tissue obtained from 275 patients with CRC (SI Appendix, Table S1 ). Significant differences in the levels of many metabolites were observed between normal tissues and tumor tissues (SI Appendix, Fig. S1 ). Unexpectedly, most of the changes were found in the adenoma stage, early in the adenoma-carcinoma sequence of CRC progression, and remained similar through all cancer stages (Fig. 1 ). S-adenosylmethionine (SAM), a methyl donor, was the most up-regulated metabolite in tumor
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Metabolic reprogramming is one of the hallmarks of cancer. However, the underlying mechanisms that regulate cancer metabolism are poorly understood. Here we performed multiomics-based analysis of paired normal-tumor tissues from patients with colorectal cancer, which revealed that the protooncogene protein MYC regulated global metabolic reprogramming of colorectal cancer by modulating 215 metabolic reactions. Importantly, this metabolic reprogramming occurred in a manner not associated with specific gene mutations in colorectal carcinogenesis. For many years, small-molecule or biologic inhibitors of MYC have been required. Here we demonstrate that knockdown of MYC downstream pyrimidine synthesis genes contributes to the suppression of colorectal cancer cell proliferation similar to MYC, and thus pyrimidine synthesis pathways could be potential targets for colorectal cancer therapy. tissue ( Fig. 1A and SI Appendix, Fig. S1 ). Glucose was the second most decreased metabolite in tumor tissue, whereas lactate was increased ( Fig. 1A and SI Appendix, Fig. S1 ), implying activation of glycolysis, termed the Warburg effect (1) . Interestingly, every amino acid except glutamine, the main substrate in glutaminolysis, was significantly accumulated in tumor tissue (SI Appendix, Fig. S1 ).
CRC progression is associated with mutations in oncogenes and tumor suppressor genes such as APC, KRAS, and TP53 (12) . We applied next-generation and Sanger sequencing technologies to detect somatic mutations in cancer-related genes in the tumor tissue. The mutation frequencies in APC, TP53, and KRAS were 76, 68, and 46%, respectively ( Fig. 2A) , which are comparable to those in previous reports (13) (14) (15) . Other mutations were found throughout the cancer stages, but these major mutations were not associated with metabolite levels in the CRC tissue ( Fig. 2 B and C) .
Next, we applied transcriptomic analysis to paired normal and tumor tissues and observed overexpression of LAT1, the protooncogene MYC, and inflammatory cytokine genes in CRC tissue (Fig. 3A) . Similar to the metabolome data (Fig. 1A) , the expression levels of metabolic genes were constant throughout the stages (Fig. 3B ). Taken together with the results of our metabolomic and transcriptomic analysis, we propose that the metabolic shift occurs at the adenoma stage of CRC, although further validation on an independent and larger cohort of normal/CRC samples particularly at this earliest stage is necessary.
Analyses of Tissue from Apc Mutant Mice. Because human clinical samples are heterogeneous entities, we performed metabolome and DNA microarray analyses on normal and adenomatous tissue obtained from the large intestines of Apc +/Δ716 mice, a genetically engineered mouse model of familial adenomatous polyposis that develops benign adenomas in the intestines (16) , and on normal tissue from wild-type C57BL/6N mice. Considerable differences were observed in metabolite levels (SI Appendix, Fig. S2 A and B) that correlated with those found in the CRC tissue (SI Appendix, Fig. S2C ). The transcriptome data were also similar to the clinical samples, demonstrating abnormal expression of Myc and inflammatory cytokine genes in adenoma tissue (SI Appendix, Fig. S3 ).
Aberrant MYC Expression Correlates with Metabolic Reprogramming.
MYC is one of the most frequently deregulated oncogenes and is estimated to regulate the expression of 15% of all genes (17, 18) , including various metabolic genes (19, 20) . In cancerous cells, deregulation of MYC expression occurs via many mechanisms (19, 21) . We found that MYC expression was up-regulated in all cancer stages, including adenomas, irrespective of the presence or absence of APC mutations ( Fig. 3 C and D) . We then explored metabolic genes that were correlatively expressed with MYC (Spearman rank-order correlation coefficient: r 2 > 0.4) (Fig. 3E ) and identified 231 unique metabolic genes (SI Appendix, Table  S3 ). Consistently, partial correlation analysis showed no significant direct relationship between MYC and a specific metabolic gene (SI Appendix, Table S3 ). The results indicate that MYC expression is a highly correlated expression of a variety of metabolic genes.
The 231 genes were involved in a total of 346 metabolic reactions and included transporters in major metabolic pathways, including purine/pyrimidine synthesis, the pentose phosphate pathway, MAPK signaling pathway, and fatty acid oxidation pathway ( Fig.  3F and SI Appendix, Table S3 ). Among them, almost all metabolic genes of the de novo purine/pyrimidine synthesis pathway were up-regulated, correlating with MYC expression (Fig. 3G and SI Appendix, Fig. S4 A and B) . Several genes in the glycolysis and pentose phosphate pathways were up-regulated, whereas those in the TCA cycle were down-regulated with aberrant MYC expression (SI Appendix, Fig. S4C ). Many genes involved in fatty acid synthesis were also up-regulated, while those participating in fatty acid oxidation were down-regulated in CRC tissue (SI Appendix, Fig. S4C ).
One-carbon metabolism involving the folate and methionine cycles has attracted attention as a driver of oncogenesis (22) . Nine one-carbon metabolism genes and three genes related to one-carbon transport, including SLC25A32 (mitochondrial folate transporter; MFT), SLC7A5 (LAT1), and SLC7A8 (LAT2), were highly expressed in conjunction with MYC expression (SI Appendix, Fig. S4C ). In addition, MYC expression is likely to be associated with DNA and histone methylation activity through increases in one carbon-related metabolites and genes [i.e., SAM (Fig. 1A) , DNMT1, DNMT3B (correlation coefficient with MYC: r 2 = 0.309)] and histone-lysine N-methyltransferase enzyme (EZH2) and a decrease in TET2 DNA demethylase (Fig. 3H) . Various genes involved in amino acid metabolism were also upor down-regulated together with aberrant MYC expression (SI Appendix, Fig. S4C) .
Consistent with the transcriptome data, we observed increased levels of lactate, the final product of glycolysis, and many metabolic intermediates in de novo purine and pyrimidine synthesis in the tumor tissues. In addition, most of the metabolites in onecarbon metabolism-related pathways, including serine, onecarbon and transsulfuration metabolism (SI Appendix, Fig. S1 ), and the products of fatty acid synthesis (i.e., palmitate and oleate) were significantly increased (Fig. 3I ).
Aberrant MYC Expression Reduces Mitochondrial Homeostasis. PINK1, a central regulator gene for mitochondrial maintenance, and a master autophagy regulator gene, TFEB (correlation coefficient with MYC: r 2 = 0.367), demonstrated the highest inverse correlation with MYC (Figs. 3E and 4A), implying inhibition of mitophagy in tumor tissue. The expression of PGC-1α, a master regulator of mitochondrial biogenesis (23, 24) , was also inversely correlated with MYC (Fig. 3E) , and the expression levels of these genes were markedly reduced in tumor tissues (Fig. 4A) .
Although mitochondrial content was little altered (Fig. 4 B and C), transmission electron microscopy (TEM) revealed an accumulation of abnormal mitochondria in cancerous (Fig. 4 D-F ) and adenomatous tissues (Fig. 4G) , with severe mitochondrial swelling, disappearance of cristae, and matrix clearing. We found that the GCN5 acetyltransferase gene, a repressor of PGC-1α-regulated transcription (25) , was highly expressed in tumor tissue (Fig. 4H) . Alongside this the promoter region of the IRF4 gene (26) , one of the transcription factors for PGC-1α, was hypermethylated ( Fig. 4I ) and thus had a decreased expression level (Fig. 4J) , resulting in suppression of PGC-1α expression (Fig. 4A) .
MYC Knockdown Resets Metabolism and Suppresses Cell Growth. To further establish the role of MYC in metabolic reprogramming, we suppressed MYC expression by siRNA in the human colorectal cancer cell line (Fig. 5A) . MYC knockdown dramatically changed the expression signatures of genes involved in major metabolic pathways, transporters, and mitochondrial biogenesis/maintenance, as well as those related to DNA and histone methylation (Fig. 5 and SI Appendix, Figs. S5 and S6) . The levels of LAT1, LAT2, DNMT3B, and EZH2 decreased, while the level of TET2 was elevated in MYC-knockdown cells (Fig. 5 A and B and SI Appendix, Fig. S5B ). The expression levels of most metabolic genes highly correlated with MYC in CRC tissue were reversed when MYC was inhibited by siRNAs in HCT116 human colorectal carcinoma cells (Fig. 5C and SI Appendix, Figs. S5A and S6) , which indicates that almost all of these gene expressions are regulated by MYC. Overall, we found that MYC regulated at least 215 metabolic reactions in major metabolic pathways, including de novo purine/pyrimidine synthesis and one-carbon metabolism, controlling 121 metabolic genes and 39 transporters ( Fig. 6 and SI Appendix, Table S3 ). Regarding glucose metabolism, aberrant *** *** *** *** *** *** *** *** *** *** *** *** *** *** *** * ** *** *** *** *** *** ** *** ** *** ** *** *** *** *** *** *** *** ** *** *** * *** The effect of major mutations on the levels of representative metabolites, namely glucose, lactate, and SAM. Although the levels of glucose, lactate, and SAM in normal and tumor tissues (n = 41) were significantly different, there were no significant differences between wild-type tumor tissue (red) and mutated tumor tissue (brick). (C) PCA of wild-type tumor tissue (open circles) and mutated tumor tissue (filled circles) based on metabolome data. Kruskal-Wallis and Dunn's posttest (B). ***P < 0.001, **P < 0.01, and *P < 0.05. Subsequently, we analyzed changes in intra-and extracellular metabolite levels between control and MYC-knockdown HCT116 cells. When MYC was suppressed, intra-and extracellular glucose levels increased, while lactate levels decreased ( Fig. 7 A and B) ; this pattern is known as the "reverse Warburg effect." Additionally, the levels of many metabolic intermediates were consistently decreased in MYC-knockdown HCT116 cells, including those involved in serine synthesis, one-carbon metabolism (Fig. 7C) , the start of de novo purine/pyrimidine metabolism, and amino acid metabolism (SI Appendix, Fig. S7 ). However, several metabolites, such as 3PG, citrate, Asp, Gln, and Pro, showed inconsistent patterns (SI Appendix, Figs. S1 and S7). A recent study demonstrated that bacterial communities were different between normal and CRC tissues (27) . This different microbe composition might be associated with the inconsistent results of the metabolites. Principal component analysis (PCA) showed that the metabolic profiles of CRC tumor tissue, Apc +/Δ716 adenomatous tissue, and HCT116 cells were similarly shifted toward the positive PC1 direction ( Fig. 7 D and E) . Taken together, these results suggest an essential role for MYC in metabolic reprogramming through the regulation of important metabolic genes.
As described above, PGC-1α (28) and PGC-1β (29) , MYC target genes, have been proposed to be master regulators of cancer metabolism (24, 30) . We therefore investigated the possible involvement of PGC-1α and PGC-1β in global regulation of colorectal cancer metabolism. However, knockdown of PGC-1α and PGC-1β caused little alteration in metabolic gene expression in a colorectal normal cell line (Fig. 7 F and G) , leading us to conclude that MYC is the master regulator of colorectal metabolism. Knockdown of MYC considerably reduced growth of HCT116 and RKO human colon carcinoma cells ( Fig. 7 H-K) . Moreover, we investigated several MYC downstream metabolic genes (SI Appendix, Table S3 ) and observed that in addition to TYMS, a target enzyme of 5-fluorouracil (Fig. 6C) , knockdown of (C) Metabolic genes (enclosed in boxes) involved in glycolysis, the pentose phosphate pathway, gluconeogenesis, serine synthesis, and one-carbon metabolism, including the folate and methionine cycles, are regulated by MYC. Metabolic genes in red boxes were up-regulated, whereas PEPCK (in a blue box) was down-regulated by MYC expression.
pyrimidine synthesis genes such as CAD, the rate-limiting enzyme in de novo pyrimidine synthesis, UMPS, and CTPS ( Fig.  6B ) blocked HCT116 and RKO cell proliferation ( Fig. 7 H-K) . However, knockdown of purine synthesis genes such as PPAT, the rate-limiting enzyme in de novo purine synthesis, GART, and ATIC ( Fig. 6B ) had no significant effect on their proliferation ( Fig. 7 H-K).
Discussion
Our multiomics analyses of paired normal and tumor tissues from patients with CRC and tissues from Apc mutant mice highlight the critical role of MYC in reprogramming CRC tissue metabolism. We obtained clear evidence that MYC regulates global metabolic reprogramming of colorectal tumor metabolism through the modulation of 215 major metabolic reactions, controlling 121 metabolic genes and 39 transporters (SI Appendix, Table S3 ), and facilitates production of cellular building blocks. MYC also reprograms several cellular processes, including those modulating mitophagy and DNA/histone methylation. Knockdown of MYC in colorectal cancer cells can reset the altered metabolism and suppress cell growth. MYC can drive cell proliferation, and our current data alone may not formally exclude the possibility that MYC indirectly regulates the metabolic genes through its effect on proliferation. However, MYC has been Mann-Whitney test was used for mouse tissue and cultured cell data, and Wilcoxon signed-rank test was used for human tissue data (D and E). One-way analysis of variance and Dunnett (F and G). ***P < 0.001, **P < 0.01, and *P < 0.05.
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demonstrated to directly control transcription of various key metabolic genes, including LDH-A and CAD (31, 32) . We thus propose that MYC is the master regulator of colorectal tumor metabolism and an attractive therapeutic target. MYC is a target gene of the Wnt signaling pathway, and thus MYC overexpression was caused by APC or β-catenin mutations in most of the colorectal tumor tissues (Fig. 3C ). However, interestingly, elevated MYC expression occurred even without these mutations (Fig. 3C ). In addition to Wnt signaling, MYC deregulation in cancer has been as a consequence of several abnormalities, including gross genetic abnormalities and aberrant activity of transcriptional factors, PI3K/AKT/mTOR signaling pathways, receptor tyrosine kinases, hormones, and growth factors (19, 21) . Therefore, we speculate that these factors may induce MYC expression, resulting in metabolic reprogramming of colorectal cancer metabolism.
Here we propose that a sufficient nutrient supply in the precancerous stage may be indispensable for cancer development and growth. These findings may have implications for future cancer prevention and therapeutic approaches targeting MYC-regulated metabolism. Unfortunately, however, finding small-molecule or biologic inhibitors of MYC has proved difficult because MYC is localized within the nucleus and does not have a deep surfacebinding pocket (33) . Therefore, MYC is not amenable to blockade by small molecules or accessible to neutralization by antibodies.
Here we have demonstrated that knockdown of MYC or MYC target pyrimidine synthesis genes such as CAD, UMPS, and CTPS, but not purine synthesis genes, can suppress colorectal cancer cell proliferation . This provides the foundation for a potential anticancer strategy in which pyrimidine synthesis pathways downstream of MYC could be an alternative target for colorectal cancer therapy.
Materials and Methods
Clinical Samples. We conducted all experiments according to a study protocol approved by the Institutional Ethics Committee of Kagawa University (Heisei 24-040) upon obtaining informed consent from all subjects. The tumor and surrounding grossly normal-appearing tissue were obtained from 275 colorectal cancer patients at the time of surgery. The normal tissues were obtained from colorectal mucosa. Regarding the tumor tissues, to minimize the effect of other cells, we excluded CRC tissues with excessive stroma or infiltrating lymphocytes using hematoxylin-eosin staining. Clinicopathological information is listed in SI Appendix, Table S1 .
Mouse Strains. Construction of an Apc
+/Δ716 strain has been described previously (34) . The strain was backcrossed to the C57BL/6N background for >20 generations. C57BL/6N mice were purchased from CLEA Japan. Mice were kept under a 12-hour light-dark cycle at ∼22°C and fed ad libitum with a CLEA CE-2 chow diet. All animal experiments were conducted according to protocols approved by the Animal Care and Use Committee of the Aichi Cancer Center Research Institute. 
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Mouse strains
Construction of an Apc +/Δ716 strain has been described previously (1) . The strain was backcrossed to the C57BL/6N background for >20 generations. C57BL/6N mice were purchased from CLEA Japan (Tokyo, Japan). Mice were kept under a 12-hour light-dark cycle at ~22C and fed ad libitum with a CLEA CE-2 chow diet. All animal experiments were conducted according to protocols approved by the Animal Care and Use Committee of the Aichi Cancer Center Research Institute.
Mouse tissue sample preparation
For metabolome analyses, intestinal polyps and normal intestinal tissue was excised from euthanized female mice, washed in ice-cold 5% w/v mannitol solution, snap-frozen in liquid nitrogen, and stored at -80C. For RNA isolation, the intestinal tissue samples were washed in PBS and pretreated with RNAlater solution (Life Technologies, Carlsbad, CA) at 4C overnight and then stored at -80C.
Total RNA isolation from mouse tissue
Total RNA from mouse tissue was isolated using an RNeasy Mini Kit (Qiagen, Venlo, Netherlands) according to the manufacturer's protocol, including on-column DNase I incubation for 15 min at room temperature to reduce genomic DNA contamination.
Cell culture
The human colorectal carcinoma cell lines HCT116 and RKO and the human normal colorectal cell line CCD841 CoN were obtained from the American Type Culture Collection (ATCC). The human rectal adenocarcinoma cell line CaR-1 and human colorectal carcinoma cell line COLO741 were obtained from the Japanese Collection of Research Bioresources (JCRB) and the European Collection of Authenticated Cell Cultures (ECACC), respectively. The cells were maintained in Dulbecco's Modified Eagle's Medium (Sigma-Aldrich, St. Louis, MO) supplemented with 10% fetal bovine serum (Equitech-Bio, Kerrville, TX) at 37C with 5% CO2. For qRT-PCR, DNA microarray, and metabolome analyses, 2×10 5 cells were seeded in a 60-mm dish, cultured for 24 h, and transfected with 100 nM ON-TARGETplus siRNAs (Dharmacon, Lafayette, CO) using Lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. For the cell proliferation assay, 5×10 4 cells were seeded in 60-mm dishes, cultured for 24 h, and transfected with 100 nM siRNAs. Three days after transfection, the cells were counted using a Cytell Cell Imaging System (GE Healthcare, Buckinghamshire, United Kingdom), following the manufacturer's instructions. The siRNA oligonucleotide sequences are listed in table S4.
Metabolite extraction from CRC and mouse tissue
The excised tissues were cut into pieces smaller than 1 cm 3 , immediately frozen in liquid nitrogen, and stored at −80°C until metabolite extraction. To extract charged metabolites and glucose, pre-weighed, deep-frozen samples (approximately 50 mg each) were completely homogenized using a cell disrupter (Shake Master NEO; Bio Medical Science, Tokyo, Japan) at 1500 rpm for 5 min after the addition of 500 µL of methanol containing internal standards [20 µM each of methionine sulfone, 2-(N-morpholino)-ethanesulfonic acid (MES) and D-camphor-10-sulfonic acid (CSA)]. The homogenate was then mixed with Milli-Q water and chloroform in a volume ratio of 5:2:5 and centrifuged at 4600 g for 15 min at 4°C. Subsequently, 300 µL of the aqueous solution was centrifugally filtered through a 5-kDa cut-off filter (Human Metabolome Technologies, Tsuruoka, Japan) to remove proteins. The filtrate was centrifugally concentrated and dissolved in 50 µL of Milli-Q water that contained reference compounds (200 µM each of 3-aminopyrrolidine and trimesate) immediately prior to metabolome analysis.
For palmitate and oleate, after the addition of 400 µL of methanol, pre-weighed, deep-frozen samples (approximately 20 mg each) were completely homogenized using a cell disrupter (Shake Master NEO; Bio Medical Science, Tokyo, Japan) at 1500 rpm for 15 min. The homogenate was then mixed with Milli-Q water and chloroform in a volume ratio of 5:2:5 and centrifuged at 2000 g for 5 min at 20°C. Subsequently, 100 µL of the supernatant was used for LC-MS/MS analysis.
Metabolite extraction from HCT116 cells
For metabolite extraction, culture medium and HCT116 cells were collected 48 h after transfection. Then, 100 µL of the collected medium was mixed with 400 µL of methanol containing 25 µM of the internal standards described above, 200 µL of Milli-Q water, and 500 µL of chloroform. The cells were washed twice with ice-cold 5% mannitol solution and covered with 1.2 mL of methanol containing 25 µM internal standards for 10 min. The resulting extracts were mixed with 200 µL of Milli-Q water and 400 µL of chloroform. The aqueous phase of the medium and cell sample solution was then subjected to ultrafiltration as described above.
Metabolome analysis
A critical issue in quantitative analysis using electrospray-based mass spectrometry is the occurrence of matrix effects that may lead to a significant difference in the response of the analytes in the sample compared to a pure standard. To overcome this issue, we used CE-MS for the global analysis of charged metabolites. CE-MS provides high resolution efficiency (theoretical plate numbers greater than 200,000/m), and metabolites are well separated. In addition, unlike LC, charged species are eluted at different migration times based on charge/size ratio in CE. Therefore, most of the charged matrix components are likely separated from analytes in CE-MS. Moreover, the injection volume in CE-MS is quite small (less than 30 nL). Therefore, CE-MS is minimally affected by matrix effects, and this technique provides high quantification accuracy for most analytes in various types of samples. The concentrations of all the charged metabolites in samples were measured by CE-TOFMS, (Agilent Technologies, Santa Clara, CA) using methods developed by the authors (2, 3) . Briefly, to analyze cationic compounds, a fused silica capillary (50 µm i.d. × 100 cm) was used with 1 M formic acid as the electrolyte (4) . Methanol/water (50% v/v) containing 0.1 µM hexakis(2,2-difluoroethoxy)phosphazene was delivered as the sheath liquid at 10 µL/min. ESI-TOFMS was performed in positive ion mode, and the capillary voltage was set to 4 kV. Automatic recalibration of each acquired spectrum was achieved using the masses of the reference standards ([ 13 C isotopic ion of a protonated methanol dimer (2 MeOH+H)] + , m/z 66.0632) and ([hexakis (2,2-difluoroethoxy) phosphazene +H] + , m/z 622.0290). To identify metabolites, relative migration times of all peaks were calculated by normalization to the reference compound 3-aminopyrrolidine. The metabolites were identified by comparing their m/z values and relative migration times to the metabolite standards. Quantification was performed by comparing peak areas to calibration curves generated using internal standardization techniques with methionine sulfone. The other conditions were identical to those described previously (2) .
To analyze anionic metabolites, a commercially available COSMO(+) (chemically coated with cationic polymer) capillary (50 µm i.d. x 105 cm) (Nacalai Tesque, Kyoto, Japan) was used with a 50 mM ammonium acetate solution (pH 8.5) as the electrolyte. Methanol/5 mM ammonium acetate (50% v/v) containing 0.1 µM hexakis(2,2-difluoroethoxy)phosphazene was delivered as the sheath liquid at 10 µL/min. ESI-TOFMS was performed in negative ion mode, and the capillary voltage was set to 3.5 kV. For anion analysis, trimesate and CAS were used as the reference and the internal standards, respectively. The other conditions were identical to those described previously (3) .
CE-TOFMS raw data were analyzed using our proprietary software MasterHands (ver, 2.17.0.10). Briefly, the data processing for each experiment included data conversion, binning data into 0.02 m/z slices, baseline elimination, peak picking, integration, and elimination of redundant features to yield the all possible peaks lists. Data matrices were generated by an alignment process based on corrected migration times, and metabolite names were assigned to the aligned peaks by matching m/z and the corrected migration times of our standards library. Relative peak areas were calculated based on the ratio of peak area divided by those of internal standards, and metabolite concentrations were calculated based on the relative peak area between the sample and standard mixture.
Glucose analysis LC-MS/MS was performed using an Agilent 1100 series HPLC system (Agilent Technologies) and an Agilent 6430 Triple Quad triple-quadrupole tandem mass spectrometer. The glucose was separated on a TSK-GEL AMIDE-80 column (2 mm i.d. × 250 mm, 5 µm; Tosoh, Tokyo, Japan) that was maintained at 80°C. The mobile phase consisted of water as solution A and acetonitrile as solution B. The elution gradient started with 75% B for 10 min, linearly decreased to 10% B for 2 min and then remained at 10% up to 17 min. The flow rate was 0.2 mL/min, and the injection volume was 0.1 µL. The MS was performed in negative ion mode, and the capillary voltage was set to 4 kV. The flow rate of heated dry nitrogen gas (heater temperature, 300°C) was maintained at 10 L/min. MS/MS with multiple reaction monitoring (MRM) detection was used. At MS/MS, the Q1 (precursor ion), Q3 (product ion), fragmentor and collision energy were set to 179.0 m/z, 89.0 m/z, 60 V and 0 V, respectively. Quantification was performed by comparing the glucose peak area to the calibration curve generated using internal standardization techniques with 2-morpholinoethanesulfonate (MES).
Palmitate and oleate analysis LC-MS/MS was performed using an Agilent 1290 Infinity HPLC system and an AB Sciex 5500 QTRAP hybrid triple-quadrupole tandem mass spectrometer. Palmitic acid and oleic acid were separated on an ACQUITY UPLC HSS T3 column (2.1 mm i.d. × 50 mm, 1.8 µm; Waters, Taunton, Ireland) that was maintained at 45°C. The mobile phase consisted of 5 mM ammonium formate aqueous solution containing 1 µM DAEDTAmethanol-acetonitrile (3:1:1, v/v/v) as solution A and isopropanol containing 5 mM ammonium formate and 1 µM DAEDTA as solution B, with a linear gradient from 0 to 40% B for 5 min and from 40 to 64% for 2.5 min, maintenance for 4.5 min, followed by 64 to 82.5% for 0.5 min, from 82.5 to 83.46% for 2.5 min and from 83.46 to 97% for 2.5 min. The flow rate was 0.3 mL/min, and the injection volume was 5 µL. The MS was performed in negative ion mode, and the capillary voltage was set to 4.5 kV. The heated dry nitrogen gas temperature, curtain gas, collision gas and ion source gas were set to 300°C, 30 psi, 6 (arbitrary units) and 50 psi, respectively. MS/MS with multiple reaction monitoring (MRM) detection was used. The declustering potential and collision energy were set to 120 V and 34 V, respectively. The MS/MS transition (Q1/Q3) settings for palmitate and oleate were 256.2/256.2 m/z and 282.2/282.2 m/z, respectively. Quantification was performed by comparing their peak areas to calibration curves generated using internal standardization techniques with reserpine.
Transcriptome analysis
Total RNA was isolated from tissue obtained from 39 colorectal cancer patients (39 normal tissue and 41 tumor tissue samples) using an RNeasy Mini Kit (Qiagen). RNA samples were subjected to expression microarray analysis. The quality of the RNA was assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies). One hundred nanogram aliquots of total RNA were used for the production of Cy3-labeled complementary RNA (cRNA), and all samples were hybridized to the SurePrint G3 Human GE 8x60K v2 microarray (Agilent Technologies). The signal values were extracted using Feature Extraction software (Agilent Technologies). The data for expression microarray analysis were analyzed using GeneSpring software (Agilent Technologies). For microarray analysis of mouse colorectal tissue, wild-type and Apc mutant female mice were euthanized at 14 weeks, and total RNA extracts were used for Cy3-labeled cRNA synthesis. The resulting cRNAs were hybridized to a Mouse GE 4x44K v2 microarray (Agilent Technologies). For analysis of HCT116 cells, total RNA was isolated from cells transfected with control or MYC siRNAs at 48 h posttransfection. The Cy3-labeled cRNAs were hybridized to SurePrint G3 Human GE 8x60K v3 microarray (Agilent Technologies). For normalization of data from human tissue and HCT116 cells, each signal value was divided by the trimmed mean calculated by excluding 2% of the highest and the lowest outliers of all signal values of each sample. For data from mouse tissue, each signal value was divided by the median of all signal values of each sample.
Quantitative real-time PCR analysis
Reverse transcription was performed using ReverTra Ace qPCR RT Master Mix (TOYOBO, Osaka, Japan). Real-time PCR was performed using SYBR Premix Ex Taq II (Tli RNaseH Plus) (Takara Bio, Ohtsu, Japan) and a StepOnePlus Real-Time PCR system (Applied Biosystems, Foster City, CA), following the manufacturer's instructions. Primers were designed using the NCBI Primer-BLAST tool and are listed in table S4.
Targeted sequence
Genomic DNA was extracted from frozen tissue samples with a QIAamp DNA Mini Kit (Qiagen) and then quantified using a Qubit dsDNA BR Assay Kit (Invitrogen) and qPCR (Illumina FFPE QC Kit). Ten nanograms of genomic DNA was used for library construction with the Ion AmpliSeq Cancer Panel v2 (ThermoFisher Scientific, Waltham, MA), which enabled us to examine mutation hotspots in 49 commonly mutated oncogenes and tumor suppressor genes (Fig. S4A) . Library DNAs were prepared by amplifying targeted regions by multiplex PCR followed by adapter DNA ligation. The quality of library DNAs was assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies). Emulsion PCR was performed with an Ion OneTouch 200 Template Kit v2 (ThermoFisher Scientific), and sequencing was performed with the Ion PGM System (ThermoFisher Scientific) according to the manufacturer's instructions. We used Torrent Suite software (ThermoFisher Scientific) for automated data analysis. For samples without hotspot mutations in the tumor suppressor genes APC or TP53, PCR amplification and Sanger sequencing of the PCR products were performed to determine whether other coding regions and splice sites in APC or TP53 contained mutations, according to a previously described protocol (5).
Transmission electron microscopy
Normal and tumor colorectal tissue samples were fixed with 2.5% glutaraldehyde in 0.1 M phosphate buffer (pH 7.4) and then post-fixed with 1% osmium tetroxide in the same buffer. They were dehydrated in a graded series of ethanol and embedded in Epon 812. Ultrathin sections were stained with uranyl acetate and lead citrate and were examined using a JEM-1400 electron microscope (JEOL, Tokyo, Japan).
Immunohistochemistry
Colorectal tissue samples were fixed in formalin, embedded in paraffin wax and sectioned into 4-µm-thick slices. The sections were incubated with mouse monoclonal primary antibodies to TOMM20 (Abcam, Cambridge, United Kingdom, ab56783; 1:100 dilution) and COX IV (Abcam, ab14744; 1:50 dilution), labeled with Histofine Simple Stain MAX PO (MULTI) (Nichirei Biosciences Inc., Tokyo, Japan, code number 424151), and then stained with 3,3'-diaminobenzidine tetrahydrochloride (DAB) solution (Nichirei Biosciences Inc., code number 415171). All sections were counterstained with hematoxylin.
Quantification of mitochondrial DNA content
For quantification of mitochondrial DNA content, the amount of mitochondrial DNA relative to nuclear genomic DNA was determined by qRT-PCR using primers for cytochrome b (a mitochondrial gene) and RPL13A (a nuclear gene), according to a previously described protocol (6) .
Methylated DNA immunoprecipitation analysis
Genomic DNA was sonicated to a size range of 100-500 bp. The resulting DNA fragments were ligated to adapters using a standard protocol. Immunoprecipitation of methylated DNA with anti-5-methyl-cytosine antibody was performed using a MagMeDIP kit (Diagenode, Liège, Belgium). Following PCR amplification of immunoprecipitated DNA, 200-300-bp fragments were size-selected and subjected to 50-bp paired-end sequencing using HiSeq 2000 (Illumina, San Diego, CA). More than 85 million reads (4.2 Gb) were obtained for each sample. The sequencing reads were mapped onto the NCBI build 37.1 (UCSC hg19) assembly of the human genome using the SOAP version 2.20 alignment tool and analyzed with the MACS version 1.4.0 algorithm. The mapped read counts at each locus were normalized with total unique mapped reads in each sample. Data visualization was conducted using GenomeJack (ver. 3.0 Revision 890, Mitsubishi Space Software, Tokyo, Japan).
Software
The data were analyzed with R (ver. 3.2.3, R Foundation for Statistical Computing, Vienna, Austria, www-R-project.org), GraphPad Prism (ver. 5.0.2, GraphPad Software Inc., San Diego, CA), and JMP (ver. 11, SAS, Cary, NC) for statistical analyses; with TM4 software (ver. 4.7.4) (7) for clustering analyses and visualizing the datasets as heat maps; and with XLStat (ver. 2014.1.09, XLStat, Paris, France) and David Bioinformatics Resources (ver. 6.7) (8, 9) for pathway analysis.
Analysis of metabolomics data
For heat map and PCA analyses of human tissue samples, only peaks detected in 50% of the subjects in both the tumor and the paired normal tissue were used to eliminate peaks detected in only a few samples. The colors in the heat maps were determined by divided the values by the median values obtained for the normal tissue. For individual metabolites of cultured cells and the medium, the number of molecules in each dish was visualized in bar graphs with the average  S.D.
To perform PCA in the human tissue samples, mouse samples, and cultured cells, metabolites consistently detected in  50% of the human tissue and cultured cells ( 1) were used. To visualize individual metabolite levels in tumor tissue, box and whiskers plots of metabolites were used. The horizontal bars represent the medians, quartiles, and 10% of both ends. Outliers ( average + 3×S.D.) were not visualized, but all data, including outliers, were subjected to statistical analyses. To visualize individual PC levels of the score plots, box and whiskers plots were used, and their horizontal bars indicated medians, quartiles and 5% of both ends. P-values were calculated using statistical analyses with two-tailed tests. P-values were corrected by false discovery rate (FDR), accommodating multiple independent tests. Error bars at bar graphs indicated the S.D. of the data. To evaluate direct association among human genes, partial correlation were calculated.
To access the correlation between mouse and human metabolomic data, the medians of tumor metabolite concentrations were divided by the medians of control metabolite concentrations, and medians of metabolite concentrations of adenomatous Apc +/Δ716 mouse tissue were divided by the medians of normal metabolite concentrations. The metabolites detected in  50% of both samples were used and outliers (jackknife α=1.19) were eliminated.
Analysis of gene expression data
To evaluate relative expression levels among multiple genes, each gene was ranked based on the ratio of the median values of tumor and normal samples. To visualize gene expression levels using box and whiskers plots, each gene expression level was divided by the median value of the control data. The treatment of outliers and horizontal bars was identical to that for the metabolomics data. For the MYC knockdown experiments only, the data were divided by the average of the controls and visualized in a bar graph with means and SDs. P-values were corrected by false discovery rate (FDR), accommodating multiple independent tests.
To access the robustness of ranking based on the correlation, we conducted bootstrapping analysis, i.e., the samples were randomly selected, allowing redundant selection to generate datasets with the same sample size, and a statistic test was performed for each dataset. This process was repeated up to 200 times. Finally, 95% confidence intervals were calculated.
To evaluate the correlation between mouse and human transcriptomic data, medians of tumor data were divided by the medians of control data, and medians of adenomatous Apc +/Δ716 mouse tissue were divided by the medians of normal data. Data with consistent gene symbols between human and mouse tissues, with KEGG E.C. numbers from 1.1 to 1.6, were selected, and outliers (jackknife α=1.18) were eliminated. 
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Fig. S1. CE-TOFMS analysis of metabolite levels in paired normal and tumor tissue obtained from 275 CRC patients.
Metabolite abbreviations are listed in Table S2 . (A) CE-TOFMS analysis of metabolite levels in colorectal normal C57BL/6N mouse tissue (blue, n = 25) and in normal (purple, n = 5) and adenomatous (orange, n = 4) Apc +/716 mouse tissue. (B) PCA of colorectal C57BL/6N mouse tissues (blue) and of normal (purple) and adenomatous (orange) Apc +/716 mouse tissues based on metabolome data. (C) Correlation between human and mouse metabolome data. One-way ANOVA and Bonferroni correction were used to determine statistical significance. ***P < 0.001, **P < 0.01 and *P < 0.05. R = 0.427 (P < 0.0001) for (C) using Spearman correlation. Correlation between human and mouse transcriptome data. One-way ANOVA and Bonferroni correction were used to determine statistical significance (B). ***P < 0.001, **P < 0.01 and *P < 0.05. R = 0.427 (P < 0.0001) and 0.294 (P<0.0001) for (D) using Spearman correlation. significance (A, B) . ***P < 0.001 and *P < 0.05. PFKM  ENO1  PKM2  LDHB  PEPCK  PGD  RPIA  TKT  ACO2  IDH3A  SDHD  PSAT  TYMS  GART  MTHFD1L  ATIC  MTR  SHMT2  MTHFD2  MFT  LAT1  LAT2  DNMT1  DNMT3B  AHCY  ACACA  MECR  PPT1  PPT2  CPT1A  CPT2  ACOX1  ACADM  ACADVL  ACAA1  ACAA2  ACADS  ACAT1  SLC25A20  ASNS  ADSL  NIT2  ALDH5A1  GLS2  ALDH4A1  PPAT  GCAT  TST  ENOPH1  MUT  HADHB  AADAT  PYCR1  PYCR2  PYCRL  DAO  ODC1  CKB  ABP1  ALDH1B1  SRM  COMT  FAH The genes highlighted in yellow exhibited changes in expression upon MYC knockdown in HCT116 cells that are opposite to those seen in tumor tissues compared with normal tissues in the CRC samples. "a" indicates a significant difference (P < 0.05) between the control and both MYC siRNAs. "b" indicates a significant difference (P < 0.05) between the control and MYC siRNA1. (B) qRT-PCR analysis of genes related to serine-and one-carbon-metabolism in HCT116 cells transfected with a control siRNA (Cont) or MYC siRNAs (n = 4 each). Student's t-test and Bonferroni correction were used to determine statistical significance. ***P < 0.001, **P < 0.01 and *P < 0.05. 3F and Table S3 ). The genes highlighted in yellow exhibited changes in expression upon MYC knockdown in HCT116 cells that are opposite to those seen in tumor tissue compared with normal tissue in CRC samples. "a" indicates a significant difference (P < 0.05) between the control and both MYC siRNAs. "b" and "c" indicate a significant difference (P < 0.05) between control and MYC siRNA1 or MYC siRNA2, respectively. Student's t-test and Bonferroni correction were used to determine statistical significance.
HK2 GPI
a GPI a PFKM a ENO1 a PKM 2 a LDHB a PEPCK b PGD a RPIA a TKT a ACO2 a IDH3A a SDHD a PSAT a TYM S a GART a M THFD1L a ATIC a M TR a SHM T2 a M THFD2 a M FT a LAT1 a LAT2 c DNM T1 a DNM T3B a AHCY a ACACA a M ECR a PPT1 a PPT2 a CPT1A c CPT2 a ACOX1 a ACADM a ACADVL a ACAA1 a ACAA2 a ACADS a ACAT1 a SLC25A20 a PRPS2 a PPAT a PFAS a PAICS a ADSL a IM PDH1 a GM PS a CAD a DHODH a UM PS a UM PK NM E1 a CTPS a ASNS a NIT2 a ALDH5A1 a GLS2 ALDH4A1 a GCAT a TST a ENOPH1 a M UT a HADHB a AADAT b PYCR1 a PYCR2 a PYCRL a DAO ODC1 a CKB a ABP1 ALDH1B1 a SRM a COM T a FAH b M IF a PRDX6 aControl siMYC1 siMYC2 Control siMYC1 siMYC2 A B POLR1B a ATR a CDK4 a POLR2D a POLA1 a PNPT1 a POLR1E a SLC25A19 a POLE3 a POLD2 a DTYMK a SLC7A1 a SLC25A17 a AMPD2 a PRIM1 b PRIM2 RRM2 SLC41A3 c POLR1D a RRM1 a GLO1 a POLR3K a SLC4A2 a SLCO4A1 a GNPDA1 a POLD1 a CCND1 b B4GALT2 a DGAT2 c TK1 ADCY3 a ADK c ACYP1 b SLC12A9 a NME7 a POLA2 a HPRT1 a POLR3H a SLC12A2 a PRPS1L1 a AGK a POLR2K b GSTP1 b LIPG NUDT5 a SLC19A1 a FUT1 c SLC39A6 a POLE2 b DCTD b SLC39A10 b GPX2 a SLC35B2 a ST3GAL2 a ZNRD1 a LAT2 a CDK2 POLR2I a GLA SLC25A15 a CDK6 a SLC12A8 a SLC11A2 DUT a SLC25A14 a SLC25A27 PGM2 b UCKL1 b SLC41A1 GNPNAT1 a TST a SLC39A13 a SLC17A4 c UGP2 a SLC4A4 a SLC25A34 SLC1A1 a SULT1A2 a SLC41A2 a SLC9A1 a SLC30A4 a PAFAH2 a SLC35D1 a IMPA1 FUCA1 a PAPSS2 a PPAP2A a RETSAT a SLC30A10 a PTPRR SLC25A23 a PAFAH1B1 b MAPK7 c SLC22A18AS a MAPK3 a B3GALT5 PLCD1 a SLC44A4 SMPD3 SULT1A4 a LDHD a SLC26A3 a PPARD a PLA2G10 c SLCO2A1 c SLC36A1 SMPD1 a SLC44A2 PIP5K1B b SLC31A2 c B3GALT1 b SLC46A3 a PMM1 c PPM1A c NEU4 b SLC37A2 c RDH5 c SLC9A3R1 SLC6A19 c SLC17A5 a RPS6KA1 DHRS9 SLC6A10P b SLC26A2 a PLCD3 a MAP2K4 a SLC6A8 a MPI SLC24A6 a PIP4K2C a SLC35A3 a SLC16A9 a LAMTOR3 b SLC35G1 a SLC22A5 a SLC44A1 a FABP2 a CD36 b MKNK1 a ENPP6 a UBC b SLC5A11 c RXRA a B3GNT2 a SLC35B3 b B3GNT5 a ACSS2 a TNFRSF1A a SLC22A18 a PLCE1 b AKR1B10 FAS a PGM1 a AKR1B1 GBA3 a ECI2 a SLC10A5 DHRS3 a SLC35A5 a SLC25A24 a SLC2A13 c SLCO4C1 a MKNK2 a TRAF6 a SLC16A12 a SLC25A46 RPS6KA5 a CDS1 c ACER1 PPM1B ACER3 c GBA a UGT2A3 b HADHA a -1 0 1 -1 0 1
Fig. S7. CE-TOFMS analysis of metabolite amounts in HCT116 cells transfected with a control siRNA or MYC siRNA (n = 4 each).
Student's t-test and FDR correlation were used to determine statistical significance. ***P <0.001, **P<0.01, *P<0.05. 
Ribulose 5-phosphate Table S3 . Candidate MYC target metabolic genes.
Total of 231 metabolic related genes that showed positively or inversely correlated with MYC expression in CRC tissues (Spearman rank order correlation coefficient: r2 > 0.4). These are used for Figure 3F . Partial correlations (pr2) of the 231 genes were calculated. All P values of partial correlations were 1.
The genes highlighted in yellow exhibit changes in expression upon MYC knockdown in HCT116 cells that are opposite to those in tumour tissues compared with normal tissues in CRC samples. *"a" indicates significant differences (P < 0.05) between HCT116 cells transfected with a control siRNA and both MYC siRNAs. "b" and "c" indicate significant differences (P < 0.05) between the control and MYC siRNA1 or MYC siRNA2, respectively. †"+" indicates genes positively regulated by MYC, whereas "-" indicates inversely regulated. Genes indicated in black are identified as candidate MYC target genes. Table S4 . Oligonucleotide sequences.
siRNA oligonucleotides MYC siRNA1 (siMYC1) 5′-GCUUGUACCUGCAGGAUCU-3′ MYC siRNA2 (siMYC2) 5′-CGAUGUUGUUUCUGUGGAA-3′ MYC siRNA3 (siMYC3) 5′-CGUCCAAGCAGAGGAGCAA-3′ CAD siRNA1 (siCAD1) 5′-GAGUAUGAGGGUCUCUUCU-3′ CAD siRNA2 (siCAD2) 5′-GGAUCAAAGCCAUUGUGCA-3′ UMPS siRNA1 (siUMPS1) 5′-CCAAUCAAAUUCCAAUGCU-3′ UMPS siRNA2 (siUMPS2) 5′-GAGUUGAUAACUCUGGCAA-3′ CTPS siRNA1 (siCTPS1) 5′-CCAUGUUGAGCCUGAACAA-3′ CTPS siRNA2 (siCTPS2) 5′-GAAACUCUAUGGAGACGCA-3′ TYMS siRNA1 (siTYMS1) 5′-CAAUGGAUCCCGAGACUUU-3′ TYMS siRNA2 (siTYMS2) 5′-GGAAUCAGAUUAUUCAGGA-3′ PPAT siRNA1 (siPPAT1) 5′-GAAAUGGUCUGGAAUGUUU-3′ PPAT siRNA2 (siPPAT2) 5′-GAAAAGAGUGGUCAUUGUA-3′ GART siRNA1 (siGART1) 5′-GGAAUAAUGCUGACCAAGA-3′ GART siRNA2 (siGART2) 5′-CAAAUACCGCCAUCUCAAU-3′ ATIC siRNA1 (siATIC1) 5′-GUUGCAUUGUCCGAUGUUU-3′ ATIC siRNA2 (siATIC2) 5′-CAGAGAAGUAUCUGAUGGU-3′ PGC-1 siRNA1 (siPGC-1-1) 5′-CAGUGAUUUCAGUAAUGAA-3′ PGC-1 siRNA2 (siPGC-1-2) 5′-CUGAAGUCCUCUUGCAAGA-3′ PGC-1 siRNA1 (siPGC-1-1) 5′-CAGAUACACUGACUACGAU-3′ PGC-1 siRNA2 (siPGC-1-2) 5′-CAAGCAUAGUCUAGGCAAA-3′ Control siRNA pool 5′-UGGUUUACAUGUCGACUAA-3′ 5′-UGGUUUACAUGUUGUGUGA-3′ 5′-UGGUUUACAUGUUUUCUGA-3′ 5′-UGGUUUACAUGUUUUCCUA-3′
Quantitative real-time PCR primers β-actin-forward 5′-CCAGCCTTCCTTCCTGGGCATGG-3′ β-actin-reverse 5′-TTGGCGTACAGGTCTTTGCGGAT-3′ MYC-forward 5′-CCACCAGCAGCGACTCTGAGGAG-3′ MYC-reverse 5′-TGCCAGGAGCCTGCCTCTTTTCC-3′ CAD-forward 5′-TGGGAGCTGCATGAAGAGCGTTG-3′ CAD-reverse 5′-TCCTCAAATGAACGCCCAATGCC-3′ EZH2-forward 5′-TGTGGACCACAGTGTTACCAGCA-3′ EZH2-reverse 5′-GTGAGAGCAGCAGCAAACTCCTT-3′ GCN5-forward 5′-TGCTGTCACCTCGAATGAGCAGG-3′ GCN5-reverse 5′-CAGGTGGTTCATCAGGTGGGTCC-3′
